Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Jan 26, 2023
spot light Spotlight

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021.
Thomas J Roberts et al. JAMA network open 2023 1 (1) e2252562

Does the use of targeted therapies for non–small cell lung cancer (NSCLC) vary across state Medicaid programs? This cross-sectional study found substantial variation in the use of targeted therapies for EGFR- and ALK-altered NSCLC across Medicaid programs, with evidence of underuse in 30 of 33 states. The observed variation was associated with Medicaid policies, oncologist density, and state gross domestic product per capita.

Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays.
Douglas A Mata et al. The New England journal of medicine 2023 1 (3) 281-283

Modern oncology care relies on the assessment of tumor genomic profiles. Although it is known that there are racial and ethnic disparities in cancer outcomes, evidence regarding disparities in access to this increasingly important step in cancer diagnosis and treatment is lacking.1 We examined the use of next-generation sequencing assays according to genetic ancestry of patients in a large cancer genomics database.

Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations.
Junyi Xin et al. Genome medicine 2023 1 (1) 4

Using the UK Biobank cohort, we further validated a significant dose-response effect of PRSCSx on incident colorectal cancer, in which the risk was 2.11- and 3.88-fold higher in individuals with intermediate and high PRSCSx than in the low score subgroup (Ptrend = 8.15 × 10-53). Notably, the detrimental effect of being at a high genetic risk could be largely attenuated by adherence to a favorable lifestyle, with a 0.53% reduction in 5-year absolute risk.

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha Julia C F et al. JAMA network open 2023 1 (1) e2252244

What is the comparative effectiveness of first-line immune checkpoint inhibitors (ICIs) vs chemotherapy in standard practice settings among patients with metastatic colorectal cancer (MCRC) with high microsatellite instability (MSI-H) determined by next-generation sequencing (NGS)? In this comparative effectiveness research study of 138 patients with MCRC and MSI-H, patients receiving first-line ICIs vs chemotherapy had significantly more favorable time to next treatment, progression-free survival, and overall survival outcomes.


news Latest News and Publications
Clinical Cancer and Direct-to-Consumer Genetic Test Result-Sharing Behavior: Findings from HINTS 2020. External Web Site Icon
Makhnoon Sukh et al. Journal of personalized medicine 2023 13(1)
Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk. External Web Site Icon
Cussenot Olivier et al. BJU international 2023
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas. External Web Site Icon
Varadi Melinda et al. Cancer medicine 2023
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. External Web Site Icon
Li Si Ni et al. BMC health services research 2023 23(1) 49
Development and early-stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient-driven approach. External Web Site Icon
Pollard Samantha et al. Health expectations : an international journal of public participation in health care and health policy 2023
DNAH7 mutations benefit colorectal cancer patients receiving immune checkpoint inhibitors. External Web Site Icon
Yang Wenjuan et al. Annals of translational medicine 2023 10(24) 1335
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. External Web Site Icon
Huang Richard S P et al. Journal for immunotherapy of cancer 2023 11(1)
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy. External Web Site Icon
Schmidt Marjanka K et al. European journal of cancer (Oxford, England : 1990) 2023 18179-91
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. External Web Site Icon
Oh Mok et al. Expert review of pharmacoeconomics & outcomes research 2023
Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes. External Web Site Icon
Vanderwal April et al. Journal of genetic counseling 2023
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer. External Web Site Icon
Abdel-Razeq Hikmat et al. Breast cancer (Dove Medical Press) 2023 151-10
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. External Web Site Icon
Kwon Daniel H et al. JCO oncology practice 2023 OP2200638
Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up. External Web Site Icon
Kotaniemi-Talonen Laura et al. Acta obstetricia et gynecologica Scandinavica 2023
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry. External Web Site Icon
Sargas Claudia et al. Cancers 2023 15(2)
MyLynch: A Patient-Facing Clinical Decision Support Tool for Genetically-Guided Personalized Medicine in Lynch Syndrome. External Web Site Icon
Knapp Stephen T et al. Cancers 2023 15(2)
Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. External Web Site Icon
Adam Felicia et al. BMC medical genomics 2023 16(1) 7
Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study. External Web Site Icon
Fintelmann Florian J et al. Respiratory research 2023 24(1) 17
Predicting Openness of Communication in Families With Hereditary Breast and Ovarian Cancer Syndrome: Natural Language Processing Analysis. External Web Site Icon
Baroutsou Vasiliki et al. JMIR formative research 2023 7e38399
Predictors of Women's Intentions to Communicate Updated Genetic Test Results to Immediate and Extended Family Members. External Web Site Icon
Winskill Carolyn et al. Public health genomics 2023
Relative Risk of Bladder and Kidney Cancer in Lynch Syndrome: Systematic Review and Meta-Analysis. External Web Site Icon
Nassour Anthony-Joe et al. Cancers 2023 15(2)

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP